Ivermectin and outcomes from Covid‐19 pneumonia: A systematic review and meta‐analysis of randomized clinical trial studies

Ivermectin is an FDA‐approved drug for a parasitic disease that has broad antiviral activity. This study aims to analyse the efficacy of ivermectin in improving the Covid‐19 outcomes. We systematically searched the PubMed, Europe PMC and ClinicalTrials.gov database using specific keywords related to...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Rev Med Virol
Päätekijät: Hariyanto, Timotius Ivan, Halim, Devina Adella, Rosalind, Jane, Gunawan, Catherine, Kurniawan, Andree
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2021
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8209939/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rmv.2265
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia